Mika, T., Strate, K., Ladigan, S., Aigner, C., Schlegel, U., Tischoff, I., . . . Schroers, R. (2019). Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes. Front Med (Lausanne).
Citação norma ChicagoMika, Thomas, et al. "Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure By Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes." Front Med (Lausanne) 2019.
Citação norma MLAMika, Thomas, et al. "Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure By Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes." Front Med (Lausanne) 2019.